Bioversys AG - Asset Resilience Ratio

Latest as of December 2024: 17.16%

Bioversys AG (BIOV) has an Asset Resilience Ratio of 17.16% as of December 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See BIOV current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

CHF6.00 Million

≈ $7.59 Million USD Cash + Short-term Investments

Total Assets

CHF34.96 Million

≈ $44.19 Million USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2024–2024)

This chart shows how Bioversys AG's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Bioversys AG total assets.

Liquid Assets Composition Over Time

This chart breaks down Bioversys AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read BIOV total liabilities for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CHF0.00	0%
Short-term Investments	CHF6.00 Million	17.16%
Total Liquid Assets	CHF6.00 Million	17.16%

Asset Resilience Insights

Good Liquidity Position: Bioversys AG maintains a healthy 17.16% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Bioversys AG Industry Peers by Asset Resilience Ratio

Compare Bioversys AG's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Tubize-Fin BR:TUB	Biotechnology	2.50%
Dianthus Therapeutics Inc. NASDAQ:DNTH	Biotechnology	63.98%
Tango Therapeutics Inc NASDAQ:TNGX	Biotechnology	62.24%
Damora Therapeutics, Inc. NASDAQ:DMRA	Biotechnology	0.00%
Wecome Pharmaceutical Co Ltd SHE:300878	Biotechnology	0.67%
Tectonic Therapeutic, Inc. NASDAQ:TECX	Biotechnology	86.66%
Relmada Therapeutics Inc NASDAQ:RLMD	Biotechnology	95.25%
MediWound Ltd F:M8W	Biotechnology	56.04%

Annual Asset Resilience Ratio for Bioversys AG (2024–2024)

The table below shows the annual Asset Resilience Ratio data for Bioversys AG.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2024-12-31	17.16%	CHF6.00 Million ≈ $7.59 Million	CHF34.96 Million ≈ $44.19 Million	--

pp = percentage points

About Bioversys AG

SW:BIOV Switzerland Biotechnology

Market Cap

$211.45 Million

CHF167.25 Million CHF

Market Cap Rank

#17466 Global

#177 in Switzerland

Share Price

CHF28.60

Change (1 day)

+1.78%

52-Week Range

CHF21.50 - CHF31.60

All Time High

CHF36.30